Tandem Investment Advisors Inc. Sells 2,244 Shares of Medpace Holdings, Inc. $MEDP

Tandem Investment Advisors Inc. lessened its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 15.8% during the first quarter, HoldingsChannel reports. The institutional investor owned 11,929 shares of the company’s stock after selling 2,244 shares during the quarter. Tandem Investment Advisors Inc.’s holdings in Medpace were worth $5,728,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its position in Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after buying an additional 404,226 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after acquiring an additional 211,411 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Medpace by 158.6% in the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock valued at $168,198,000 after acquiring an additional 183,645 shares in the last quarter. Norges Bank bought a new stake in shares of Medpace during the 4th quarter valued at about $102,156,000. Finally, Goldman Sachs Group Inc. boosted its position in shares of Medpace by 92.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock valued at $194,920,000 after acquiring an additional 166,654 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Insider Transactions at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 20.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

MEDP has been the subject of several recent analyst reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Barclays lowered their target price on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Royal Bank Of Canada cut their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and increased their price target for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Finally, Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Two investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Medpace currently has an average rating of “Hold” and an average price target of $469.50.

Medpace Trading Down 0.0%

MEDP opened at $537.73 on Friday. The stock has a 50-day moving average price of $478.10 and a 200-day moving average price of $494.76. Medpace Holdings, Inc. has a 12-month low of $306.70 and a 12-month high of $628.92. The stock has a market capitalization of $15.36 billion, a P/E ratio of 33.80, a PEG ratio of 2.69 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating the consensus estimate of $3.74 by $0.54. The firm had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company’s revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the company earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.